Treatment-Resistant Depression - The Current Antidepressants Pipeline

Characterized by loss of interest, happiness and reactiveness to external stimuli, depression has emerged as a chronic mental condition, affecting approximately 3.8% of the population, as estimated by the World Health Organization. Although depression can affect individuals of any gender at any age, on average, it is believed to first appear during late teens to mid-20’s. Depressive disorders have been observed to contribute significantly to the growing economic burden. In this context, studies have revealed that loss of productivity associated with depressive disorders costs over USD 1 trillion per year to the global economy. 

Considering the grave impact and high prevalence of these disorders, a number of effective therapeutics modalities have been approved / are under development. It is worth noting that most of the approved therapies for depressive disorders either demonstrate delayed therapeutic response, or no response at all (primarily in the case of treatment-resistant depression). This has prompted pharmaceutical stakeholders to develop therapeutic interventions with novel mechanisms of action in order to efficiently treat depression. 

Roots Analysis has conducted an exhaustive study on the Depressive Disorders Market featuring the current market landscape, competitive landscape and future opportunity, over a span of 10 years.

Discover the Details on Current Pipeline for Treatment Resistant Depression, The Driving Factors, Key Developers and Future Perspectives

This article highlights the current pipeline of treatment-resistant disorders, driving factors, key companies engaged in the development of such therapies and the future perspectives.

Table 1: Treatment Resistant Depression Pipeline: Sample List of Industry Sponsored Therapies

Spravato, nasal spray approved for treatment resistant depression patients, has been consistently witnessed revenue growth. According to the annual results published by Johnson & Johnson, the drug brought in revenues of $689 million worldwide during full year 2023, a growth of 84% over the previous year. 85.5% of the sales were driven by the biggest market for the drug, the US.

Key Driving Factors 

The growing global burden of treatment-resistant disorders and the limited access to precise treatment options have prompted significant research and development activity in the depressive disorders market. With the presence of only one FDA approved drug for TRD, the industry stakeholders are actively evaluating the drugs indicated for depressive disorders, for their specific applications in the treatment of treatment-resistant depression.

Key Treatment Resistant Depression Therapy Developers

Below, we have listed a sample list of companies engaged in the development of treatment-resistant depression therapies:

Future Perspective

The development of treatment resistant depression therapies appears promising, owing to the rapidly increasing prevalence of the disease and growing global economic burden. The research and development efforts, coupled with the funding activity in the treatment-resistant depression market demonstrates the need for effective and targeted solutions. As research and development efforts continue, we anticipate lowered cost of treatment and managed adverse event rate associated with treatment-resistant depression therapies.

Wish to Gain an In-Depth Analysis on the Depressive Disorders Market?

We have conducted in-depth research on the market landscape of depressive disorder therapies, understanding the stage of development, competitive landscape, market opportunity, key trends and future outlook. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com